REVVITY, INC. is 1.4x more valuable than Bio-Rad Laboratories, Inc. by market capitalization ($11.30 B vs $8.09 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RVTY | BIO |
|---|---|---|
| Market cap | $11.30 B | $8.09 B |
| US-listed rank | #873 | #1065 |
| Revenue (latest FY) | $2.86B | $2.58B |
| Net income (latest FY) | $241.20M | $759.90M |
| Net margin | 8.4% | 29.4% |
| P/E (trailing FY) | 46.8 | 10.6 |
| SEC filings | 1,736 | 1,494 |
REVVITY, INC. is 1.4x more valuable than Bio-Rad Laboratories, Inc. by market capitalization ($11.30 B vs $8.09 B).
In their latest fiscal years, REVVITY, INC. reported $2.86B in revenue while Bio-Rad Laboratories, Inc. reported $2.58B.
Full pages: REVVITY, INC. and Bio-Rad Laboratories, Inc., or browse the full rankings.